Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
HANGZHOU, China, April 22, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon receptor (GCGR), and Glucagon-like peptide-1 receptor (GLP-1R) has...
Samsung Biologics reports first quarter 2025 financial results
Recorded Q1'25 consolidated revenue of KRW 1.3 trillion Recorded Q1'25 consolidated operating profit of KRW 486.7 billion Company expected to maintain steady growth momentum in 2025 driven by enhanced operational efficiency and diverse service offerings INCHEON, South Korea, April 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development...
United Imaging and IHH Healthcare Forge Strategic Partnership to Enhance Global Access to Advanced Imaging Technologies
SHANGHAI, April 23, 2025 /PRNewswire/ -- April 10, 2025, United Imaging, a global leader in medical imaging and radiotherapy equipment, has signed a memorandum of understanding (MOU) with IHH Healthcare, a world-leading integrated healthcare provider. The agreement, announced during the China International Medical Equipment Fair (CMEF) 2025, marks the beginning of a strategic partnership aimed at improving global...
Smartee GS Tech Revitalizes Sydney Orthodontics: Prof. Gang Shen Returns to Academic Origins with Breakthrough Clear Aligners Therapy
SYDNEY, April 22, 2025 /PRNewswire/ -- Over 30 leading orthodontists gathered at the University of Sydney for a landmark seminar on GS Mandibular Repositioning Therapy, led by Prof. Gang Shen, Chief R&D Scientist of Smartee Denti-Technology. The event marked both a homecoming for Prof. Shen, whose foundational research at Sydney University (2004-2008) shaped Smartee's globally adopted GS system in an early form, and a...
GenScript Biotech and NSG Bio Form Strategic Partnership to Drive Biotechnology Innovation
SINGAPORE, April 23, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in biotechnology research services, and NSG Bio, Singapore's premier biotech incubator, today announced a strategic partnership designed to accelerate innovation and growth within the biotechnology sector. MoU signing ceremony between GenScript and NSG Bio Through this partnership,...
Investment of Approx. USD 4.5 Million in Development of Diagnostics for Tuberculosis to Partners Including Fujirebio and University Hospital Heidelberg
TOKYO, April 23, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately JPY 679 million (USD 4.5 million1) for the development of diagnostics for tuberculosis, in addition to an investment of approximately JPY 15.9 million (USD 0.1 million1) for a drug discovery project for Chagas disease and leishmaniasis.2 Investment of approximately JPY 679 million...
Eyebright Medical Published its 2024 Environmental, Social and Governance Report
Commitment to Sustainable Development, Social Responsibility, and Corporate Governance HONG KONG, April 23, 2025 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collectively known as the "Group") is proud to announce that the Company has published its 2024 Environmental, Social and Governance...
VARON Advocates for Sustainability on Earth Day with Eco-Friendly Oxygen Solutions
NEW YORK, April 23, 2025 /PRNewswire/ -- This Earth Day, VARON is proud to reaffirm its commitment to both respiratory health and environmental responsibility. As a global leader in oxygen concentrator technology, VARON continues to advance sustainable innovation, offering eco-friendly alternatives to traditional oxygen delivery systems. By designing energy-efficient, long-lasting, and low-emission medical devices,...
Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to...
- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 mg doses. - ASC30 oral once-daily tablet also demonstrated a 4.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of...
FDA Grants Authorisation for Minder®, the First and Only Implantable Continuous EEG Monitor Approved in US
The Australian-developed Minder system is an implantable device for continuous monitoring of brain activity in patients with epilepsy, developed to address the shortcomings in current electroencephalogram technologies The FDA has granted authorisation for Minder under its De Novo pathway creating a new classification of device, allowing for marketing and sale of the device in the US for patients...
